3rd line Erlotinib for lung cancer in Asia may be as cost-effective as in the Western world

Lung Cancer

Volumn 76, Issue 3, 2012, Pages 499-500

  Lin, Ching Chan ^a   Hsia, Te Chun ^a   Chien, Chun Ru ^a,b  

^a CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

3rd line; Cost; Cost effectiveness; Effectiveness; Erlotinib; Lung cancer; Taiwan

Indexed keywords

ERLOTINIB;

ASIA; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; HUMAN; LETTER; LUNG CANCER; PRIORITY JOURNAL; TAIWAN; TREATMENT OUTCOME; WESTERN HEMISPHERE;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; PROTEIN KINASE INHIBITORS; QUINAZOLINES;

EID: 84860536599     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2012.03.022     Document Type: Letter

References (10)

1. Cromwell I, van der Hoek K, Malfair Taylor SC, Melosky B, Peacock S. Erlotinib or best supportive care for third-line treatment of advanced non-small-cell lung cancer: a real-world cost-effectiveness analysis. Lung Cancer, in press. doi:10.1016/j.lungcan.2011.12.003.
2. Ma B.B., Hui E.P., Mok T.S. Population-based differences in treatment outcome following anticancer drug therapies. Lancet Oncol 2010, 11:75-84.
3. Carlson J.J. Erlotinib in non-small-cell lung cancer: a review of the clinical and economic evidence. Expert Rev Pharmacoecon Outcomes Res 2009, 9:409-416.
4. Lyseng-Williamson K.A. Erlotinib: a pharmacoeconomic review of its use in advanced non-small cell lung cancer. Pharmacoeconomics 2010, 28:75-92.
5. Bongers M.L., Coupé V.M., Jansma E.P., Smit E.F., Uyl-de Groot C.A. Cost effectiveness of treatment with new agents in advanced non-small-cell lung cancer: a systematic review. Pharmacoeconomics 2012, 30:17-34.
6. National Health Insurance Research Database, Taiwan. [accessed 14.01.12]. http://w3.nhri.org.tw/nhird//en/Background.html.
7. Chien CR, Su SY, Cohen L, Lin HW, Lee RT, Shih YC. Use of Chinese medicine among survivors of nasopharyngeal carcinoma in Taiwan: a population-based study. Integr Cancer Ther, in press. doi:10.1177/1534735411403308.
8. Chien C.R., Lin H.W., Yang C.H., Yang S.N., Wang Y.C., Kuo Y.C., et al. High case volume of radiation oncologists is associated with better survival of nasopharyngeal carcinoma patients treated with radiotherapy: a multifactorial cohort analysis. Clin Otolaryngol 2011, 36:558-565.
9. Exchange rage. [accessed 23.01.12]. http://www.taiwanrate.org/exchange_rate_CAD_.php%3Fforex=2009/06/30.
10. Code of Federal Regulations. [accessed 25.01.12]. http://www.hhs.gov/ohrp/policy/ohrpregulations.pdf.